Literature DB >> 8897558

Host defense within the urinary tract. II. Signal transducing events activate the uroepithelial defense.

W Mannhardt1, M Putzer, F Zepp, H Schulte-Wissermann.   

Abstract

It has been shown previously that the interaction between uroepithelial cells (UEC) from healthy donors and adherent. Escherichia coli suppresses bacterial growth in vitro. The following study was performed to investigate the nature of membrane signal transduction mechanisms involved in this process. UEC/E. coli cocultures were established in the presence of substances known to modulate transmembranous signals. Inhibition of calcium flux, either by calcium channel-blocking substances or by a calmodulin antagonist, depressed the antibacterial UEC function of "healthy" UEC. In contrast, receptor/ligand-induced stimulation of G-proteins, activation of the adenylate cyclase, and the increase of intracellular cyclic AMP levels by cytoplasmatic phosphodiesterase did not increase the antibacterial capacity of healthy UEC. However, the antibacterial function of defense-deficient UEC from patients with recurrent idiopathic urinary tract infection could be reconstituted by this treatment to almost normal levels. In conclusion, the antibacterial UEC defense function is activated by transmembranous signals from bacteria attached to the host cell surface. Activation involves the adenylate cyclase pathway. Activation of the phosphoinositol pathway may contribute to intracellular calcium fluxes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8897558     DOI: 10.1007/s004670050163

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  21 in total

Review 1.  Transmembrane signalling in T cells.

Authors:  S Damjanovich; J Szöllösi; L Trón
Journal:  Immunol Today       Date:  1992-08

Review 2.  Sphingolipids and cell function.

Authors:  L R Ballou
Journal:  Immunol Today       Date:  1992-09

Review 3.  Transmembrane signals in the activation of T lymphocytes by mitogenic antigens.

Authors:  J W Hadden
Journal:  Immunol Today       Date:  1988 Jul-Aug

Review 4.  Forskolin: its biological and chemical properties.

Authors:  K B Seamon; J W Daly
Journal:  Adv Cyclic Nucleotide Protein Phosphorylation Res       Date:  1986

Review 5.  Pathogenic factors in recurrent urinary tract infections and renal scar formation in children.

Authors:  W Mannhardt; O Schofer; H Schulte-Wissermann
Journal:  Eur J Pediatr       Date:  1986-10       Impact factor: 3.183

Review 6.  Pathogenesis of urinary tract infections. Bacterial adherence, bladder defense mechanisms.

Authors:  C L Parsons
Journal:  Urol Clin North Am       Date:  1986-11       Impact factor: 2.241

Review 7.  Regulation of transmembrane signaling by receptor phosphorylation.

Authors:  D R Sibley; J L Benovic; M G Caron; R J Lefkowitz
Journal:  Cell       Date:  1987-03-27       Impact factor: 41.582

Review 8.  Virulence factors in Escherichia coli urinary tract infection.

Authors:  J R Johnson
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

9.  Bacterial adherence and hemolysin production from Escherichia coli induces histamine and leukotriene release from various cells.

Authors:  J Scheffer; W König; J Hacker; W Goebel
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

10.  Glycolipid receptors for uropathogenic Escherichia coli on human erythrocytes and uroepithelial cells.

Authors:  H Leffler; C Svanborg-Edén
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

View more
  2 in total

1.  Angiotensin-converting enzyme inhibitor treatment and the development of urinary tract infections: a prescription sequence symmetry analysis.

Authors:  Koen B Pouwels; Sipke T Visser; H Jens Bos; Eelko Hak
Journal:  Drug Saf       Date:  2013-11       Impact factor: 5.606

2.  Idiopathic hypercalciuria associated with urinary tract infection in children.

Authors:  Vesna D Stojanović; Biljana O Milosević; Milesa B Djapić; Jelena D Bubalo
Journal:  Pediatr Nephrol       Date:  2007-06-01       Impact factor: 3.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.